PharmaCyte Biotech (PMCB) Common Equity (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Common Equity of $33.3 million for Q2 2026, down 35.84% year-over-year from $51.9 million in Q2 2025, and down 12.64% quarter-over-quarter from $38.1 million in Q1 2026.
PharmaCyte Biotech (PMCB) Common Equity (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Common Equity for 16 consecutive years, with $33.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 35.84% year-over-year to $33.3 million; the TTM figure through Apr 2026 stood at $33.3 million (down 35.84% YoY), while the FY2026 annual figure was $33.3 million, down 35.84% from the prior year.
- Common Equity eased to $33.3 million in Q2 2026 per PMCB's latest filing, from $38.1 million in the prior quarter.
- Across five years, Common Equity topped out at $91.3 million in Q1 2022 and bottomed at $27.6 million in Q2 2024.
- Historically, Common Equity has averaged $53.7 million across 5 years, with a median of $43.5 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity soared 1410.68% — and 2024, when it tumbled 61.97%.
- PharmaCyte Biotech's Common Equity stood at $81.0 million in 2022, then tumbled by 54.63% to $36.8 million in 2023, then gained by 18.18% to $43.5 million in 2024, then declined by 18.91% to $35.2 million in 2025, then fell by 5.51% to $33.3 million in 2026.
- Business Quant data shows PMCB's Common Equity at $33.3 million in Q2 2026, $38.1 million in Q1 2026, and $35.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | PharmaCyte Biotech | 4.48 Mn | 4.48 Mn | - | 33.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 33.29 Mn |
| Jan 31, 2026 | 38.11 Mn |
| Oct 31, 2025 | 35.24 Mn |
| Jul 31, 2025 | 43.59 Mn |
| Apr 30, 2025 | 51.89 Mn |
| Jan 31, 2025 | 40.25 Mn |
| Oct 31, 2024 | 43.45 Mn |
| Jul 31, 2024 | 47.71 Mn |
| Apr 30, 2024 | 27.65 Mn |
| Jan 31, 2024 | 31.37 Mn |
| Oct 31, 2023 | 36.77 Mn |
| Jul 31, 2023 | 39.19 Mn |
| Apr 30, 2023 | 72.69 Mn |
| Jan 31, 2023 | 77.12 Mn |
| Oct 31, 2022 | 81.04 Mn |
| Jul 31, 2022 | 86.30 Mn |
| Apr 30, 2022 | 89.92 Mn |
| Jan 31, 2022 | 91.33 Mn |
| Oct 31, 2021 | 92.12 Mn |
| Jul 31, 2021 | 5.71 Mn |